Mouse Monoclonal CD30 Antibody

CD30. a transmembrane glycoprotein in the tumor necrosis factor receptor (TNFR) superfamily, is primarily expressed on activated lymphocytes and malignant cells in certain lymphomas, including Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). Its restricted expression in healthy tissues makes it an attractive therapeutic target. CD30 antibodies were initially developed as naked monoclonal antibodies (e.g., SGN-30) to induce apoptosis or immune-mediated cytotoxicity. However, clinical efficacy was limited, prompting the development of antibody-drug conjugates (ADCs). Brentuximab vedotin, an ADC combining an anti-CD30 antibody with the microtubule-disrupting agent MMAE, revolutionized treatment upon its 2011 approval. It delivers targeted chemotherapy to CD30-positive cells, improving outcomes in relapsed/refractory HL and ALCL. Beyond ADCs, CD30-targeting bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapies are under investigation. Research also explores CD30’s role in modulating immune responses, as it participates in co-stimulatory signaling pathways. Despite successes, challenges like resistance mechanisms and optimizing combination regimens remain active areas of study. CD30 antibodies exemplify the shift toward precision oncology, balancing targeted efficacy with reduced off-tumor toxicity. Ongoing trials aim to expand applications to other CD30-positive malignancies and refine biomarker-driven approaches.